https://cvvr.hms.harvard.edu/wp-content/uploads/2017/07/20170724-vaccine-hiv.jpg11561157Academic Web Pageshttps://cvvr.hms.harvard.edu/wp-content/uploads/2020/03/cvvr-header-banner-long-white-bg.pngAcademic Web Pages2017-07-24 14:30:002019-12-29 11:13:53Experimental HIV vaccine regimen is well-tolerated, elicits immune responses
Beth Israel Deaconess Medical Center Press Release
Mosaic-based vaccine includes characteristics from several common strains of HIV.
In the APPROACH multi-site, randomized and controlled study of 393 healthy people in five countries, investigational vaccines were well-tolerated and elicited antibody responses in 100 percent of volunteers.
https://cvvr.hms.harvard.edu/wp-content/uploads/2018/07/HIVimage.jpg533800Academic Web Pageshttps://cvvr.hms.harvard.edu/wp-content/uploads/2020/03/cvvr-header-banner-long-white-bg.pngAcademic Web Pages2017-07-24 14:00:002019-12-29 11:13:38Investigational Preventative HIV Vaccine Well-Tolerated, Elicited Antibody Responses in Early Clinical Trials
By Jennifer Graham Johnson & Johnson, July 19th, 2017
As the International AIDS Society Conference on HIV Science kicks off in Paris on July 23, we’re spotlighting researchers who’ve dedicated their life’s work to tackling the epidemic in groundbreaking ways.
https://cvvr.hms.harvard.edu/wp-content/uploads/2017/07/Capture.png3491158Academic Web Pageshttps://cvvr.hms.harvard.edu/wp-content/uploads/2020/03/cvvr-header-banner-long-white-bg.pngAcademic Web Pages2017-07-19 15:58:002019-11-06 11:17:124 Amazing Men and Women at the Forefront of HIV Work
By: Matthew Disler Harvard Magazine, May 8th, 2017
To understand the outbreak of a disease like Zika, and ultimately to fight it, researchers must work on multiple levels. There are questions of molecules and chemical processes: how does the virus infect a cell, and what components provoke an immune response that can be harnessed for treatments and vaccines? On a larger scale, there are questions about populations. How does a pathogen discovered in Uganda spread from French Polynesia to Brazil and the Caribbean? How do families and individuals cope with infants born with complications from the disease, like microcephaly (an abnormally small head size) and neurological damage, whose lasting effects still have not been fully determined? Harvard researchers have already made strides at all of these levels, and, as North America prepares for another outbreak this summer, now seek to answer further questions.
https://cvvr.hms.harvard.edu/wp-content/uploads/2017/05/zika.jpg1000750Academic Web Pageshttps://cvvr.hms.harvard.edu/wp-content/uploads/2020/03/cvvr-header-banner-long-white-bg.pngAcademic Web Pages2017-05-08 14:00:002019-12-29 11:16:27Studying Zika
A new study has demonstrated that combining an experimental vaccine with an innate immune stimulant may help lead to viral remission in people living with HIV. In animal trials, the combination decreased levels of viral DNA in peripheral blood and lymph nodes, and improved viral suppression and delayed viral rebound following discontinuation of anti-retroviral therapy (ART).
https://cvvr.hms.harvard.edu/wp-content/uploads/2016/11/image-asset-2.jpeg357540Academic Web Pageshttps://cvvr.hms.harvard.edu/wp-content/uploads/2020/03/cvvr-header-banner-long-white-bg.pngAcademic Web Pages2016-11-09 17:56:002019-12-29 11:22:33New therapeutic vaccine approach holds promise for HIV remission
https://cvvr.hms.harvard.edu/wp-content/uploads/2016/09/image-asset-3.jpeg8001200Academic Web Pageshttps://cvvr.hms.harvard.edu/wp-content/uploads/2020/03/cvvr-header-banner-long-white-bg.pngAcademic Web Pages2016-09-14 20:21:002019-12-29 11:23:32Beth Israel Is Launching a Zika Vaccine Trial
https://cvvr.hms.harvard.edu/wp-content/uploads/2016/08/image-asset.gif649649Academic Web Pageshttps://cvvr.hms.harvard.edu/wp-content/uploads/2020/03/cvvr-header-banner-long-white-bg.pngAcademic Web Pages2016-08-22 16:41:002019-12-29 11:25:08The Race for a Zika Vaccine
by Linda Carroll and Samuel Sarmiento, MD NBC Health, August 4th, 2016
The race to develop a safe and effective vaccine against the Zika virus got one step closer Thursday, when a team of researchers reported positive results in the latest round of testing in monkeys.
https://cvvr.hms.harvard.edu/wp-content/uploads/2016/08/image-asset-4.jpeg303540Academic Web Pageshttps://cvvr.hms.harvard.edu/wp-content/uploads/2020/03/cvvr-header-banner-long-white-bg.pngAcademic Web Pages2016-08-04 16:04:002019-12-29 11:27:51‘Striking’ Results from Early Zika Vaccine Trial
https://cvvr.hms.harvard.edu/wp-content/uploads/2016/08/markey-2-image-asset.png304456Academic Web Pageshttps://cvvr.hms.harvard.edu/wp-content/uploads/2020/03/cvvr-header-banner-long-white-bg.pngAcademic Web Pages2016-08-04 15:29:002019-12-29 11:21:30U.S. Senator Ed Markey Visits CVVR
https://cvvr.hms.harvard.edu/wp-content/uploads/2016/07/redsox-0-1.jpeg13951433Academic Web Pageshttps://cvvr.hms.harvard.edu/wp-content/uploads/2020/03/cvvr-header-banner-long-white-bg.pngAcademic Web Pages2016-07-11 14:01:002019-12-30 07:38:52The Boston Red Sox Celebrate the Center for Virology and Vaccine Research
Experimental HIV vaccine regimen is well-tolerated, elicits immune responses
/in NewsResults from early-stage NIH-funded trial support further development of candidate vaccines.
Investigational Preventative HIV Vaccine Well-Tolerated, Elicited Antibody Responses in Early Clinical Trials
/in NewsMosaic-based vaccine includes characteristics from several common strains of HIV.
In the APPROACH multi-site, randomized and controlled study of 393 healthy people in five countries, investigational vaccines were well-tolerated and elicited antibody responses in 100 percent of volunteers.
4 Amazing Men and Women at the Forefront of HIV Work
/in NewsAs the International AIDS Society Conference on HIV Science kicks off in Paris on July 23, we’re spotlighting researchers who’ve dedicated their life’s work to tackling the epidemic in groundbreaking ways.
Studying Zika
/in NewsTo understand the outbreak of a disease like Zika, and ultimately to fight it, researchers must work on multiple levels. There are questions of molecules and chemical processes: how does the virus infect a cell, and what components provoke an immune response that can be harnessed for treatments and vaccines? On a larger scale, there are questions about populations. How does a pathogen discovered in Uganda spread from French Polynesia to Brazil and the Caribbean? How do families and individuals cope with infants born with complications from the disease, like microcephaly (an abnormally small head size) and neurological damage, whose lasting effects still have not been fully determined? Harvard researchers have already made strides at all of these levels, and, as North America prepares for another outbreak this summer, now seek to answer further questions.
New therapeutic vaccine approach holds promise for HIV remission
/in NewsA new study has demonstrated that combining an experimental vaccine with an innate immune stimulant may help lead to viral remission in people living with HIV. In animal trials, the combination decreased levels of viral DNA in peripheral blood and lymph nodes, and improved viral suppression and delayed viral rebound following discontinuation of anti-retroviral therapy (ART).
Beth Israel Is Launching a Zika Vaccine Trial
/in NewsThe trial could start as early as October, doctors say.
The Race for a Zika Vaccine
/in NewsIn the throes of an epidemic, researchers investigate how to inoculate against the disease.
‘Striking’ Results from Early Zika Vaccine Trial
/in NewsThe race to develop a safe and effective vaccine against the Zika virus got one step closer Thursday, when a team of researchers reported positive results in the latest round of testing in monkeys.
U.S. Senator Ed Markey Visits CVVR
/in NewsThe Boston Red Sox Celebrate the Center for Virology and Vaccine Research
/in News